Fiztasovimab (NPC-21, EV2038), a fully human IgG1lambda monoclonal antibody (mAb), targets human cytomegalovirus (hCMV). It exerts its neutralizing activity through binding to the antigenic domain 1 of glycoprotein B on the hCMV envelope, effectively inhibiting cell-to-cell transmission of hCMV [1].
CAS Number:
[2467411-25-0]
Target:
Virus Protease
* VAT and and shipping costs not included. Errors and price changes excepted
